(Q57278179)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Marie-Germaine Bousser

1

Marie-Germaine Bousser

0 references

Peter M. Rothwell

9

Peter M Rothwell

0 references

0 references

7

Michael G Hennerici

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

8

Heinrich P Mattle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

PERFORM Study Investigators

2 February 2020

12

PERFORM Study Investigators

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Pierre Amarenco

2

Pierre Amarenco

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Angel Chamorro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Marc Fisher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Ian Ford

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Kim M Fox

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Agnès de Cordoüe

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Marie-Dominique Fratacci

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Peter M Rothwell

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

25 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

9782

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

2013-2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Counci

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Antithrombotic agents in the prevention of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

New P2Y(12) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

TP receptor antagonism: a new concept in atherothrombosis and stroke prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Two isoforms of cyclooxygenase contribute to augmented endothelium-dependent contractions in femoral arteries of 1-year-old rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Role of prostacyclin in the cardiovascular response to thromboxane A2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960600-4

7 January 2021

10.1016/S0140-6736(11)60600-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21616527%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference